After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

"We're excited to achieve the first milestone of our collaboration with Merck and continue our work to improve biologic ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Kineta (KANT)announced at the Society for Immunotherapy in Cancer in Houston, TX an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as ...

Education: University of Virginia, BA in environmental science, 1998; University of Wisconsin, MS in atmospheric science, 2000 Jason Samenow has loved weather since he was a boy. At the University ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Even Duncan Idaho gets nervous. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. I’m terrified of being on stage. I’m really scared and ...

Davis, chairman and chief executive officer, Merck. “Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

The Black Insurrectionist's i a white man whose real name is Jason Palmer, according to an Associated Press investigation. An investigation by the Associated Press has revealed that the individual ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...